Mega Genomics

Mega Genomics Liabilities

The The Liabilities of Mega Genomics (6667.HK) as of Oct 17, 2026 is 258.33 M CNY. In the previous year, The Liabilities was 144.41 M CNY — a change of 78.89% (higher).

Liabilities

258.33 MCNY

YoY

78.89%

Last updated:

In 2025, Mega Genomics's total liabilities amounted to 258.33 M CNY, a 78.89% difference from the 144.41 M CNY total liabilities in the previous year.

The Mega Genomics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
266.45 M CNY
Jan 1, 2020
277.18 M CNY
Jan 1, 2021
90.62 M CNY
Jan 1, 2022
102.30 M CNY
Jan 1, 2023
151.72 M CNY
Jan 1, 2024
144.41 M CNY
Jan 1, 2025
258.33 M CNY
The Mega Genomics Liabilities history
YEARLiabilitiesYoY
258.33 MCNY+78.89%
144.41 MCNY-4.81%
151.72 MCNY+48.30%
102.30 MCNY+12.89%
90.62 MCNY-67.31%
277.18 MCNY+4.03%
266.45 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Mega Genomics's Liabilities

Mega Genomics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Mega Genomics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Mega Genomics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Mega Genomics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Mega Genomics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Mega Genomics stock

The Liabilities of Mega Genomics is 258.33 M CNY in 2025.

The Liabilities of Mega Genomics changed from 144.41 M CNY to 258.33 M CNY, representing a 78.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Mega Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Mega Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Mega Genomics